Historical and Current Perspective in the Use of Thyroid Extracts for the Treatment of Hypothyroidism |
| |
Institution: | 1. Division of Neurosurgery, Università degli Studi di Napoli “Federico II”, Naples, Italy;2. Division of Endocrinology, Università degli Studi di Napoli “Federico II”, Naples, Italy;3. Department of Advanced Biomedical Sciences, Section of Pathology, Università degli Studi di Napoli “Federico II”, Naples, Italy;1. Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Germany;2. Feuerlein Center on Translational Addiction Medicine (FCTS), University of Heidelberg, Germany;3. Department of Biostatistics, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Germany;4. Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Germany;5. Department of Psychiatry & Psychotherapy, University Medical Center, Hamburg, Martinistr. 52, 20246 Hamburg, Germany;1. Section of Hematology and Stem Cell Transplantation, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee;2. Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin;3. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington;4. Center for International Blood & Marrow Transplant Research, National Marrow Donor Program, Minneapolis, Minnesota;5. Department of Pathology, Stanford Medical School, Stanford University, Stanford, California;6. Germany National Bone Marrow Registry, Ulm, Germany;7. Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, Minnesota |
| |
Abstract: | Objective: To describe the history, refinements, implementation, physiology, and clinical outcomes achieved over the past several centuries of thyroid hormone replacement strategies.Methods: A Medline search was initiated using the following search terms: bioidentical thyroid hormone, thyroid hormone extract, combination thyroxine (T4) and tri-iodothyronine (T3) therapy, homeopathic thyroid hormone therapy, and thyroid hormone replacement. Pertinent articles of interest were identified by title (and where available abstract) for further review. Additional references were identified during a review of the identified literature.Results: A rich history of physician intervention in thyroid dysfunction was identified dating back more than 2 millennia. Although not precisely documented, thyroid ingestion from animal sources had been used for centuries but was finally scientifically described and documented in Europe over 130 years ago. Since the reports by Bettencourt and Murray, there has been a continuous documentation of outcomes, refinement of hormone preparation production, and updating of recommendations for the most effective and safe use of these hormones for relieving the symptoms of hypothyroidism. As the thyroid extract preparations contain both levothyroxine (LT4) and liothyronine (LT3), current guidelines do not endorse their use as controlled studies do not clearly document enhanced objective outcomes compared with LT4 monotherapy. Among current issues cited, the optimum ratio of LT4 to LT3 has yet to be determined, and the U.S. Food and Drug Administration (FDA) does not appear to be monitoring the thyroid hormone ratios or content in extract preparations on the market. Taken together, these limitations are important detriments to the use of thyroid extract products.Conclusion: The evolution of thyroid hormone therapies has been significant over the extended period of time they have been in use to treat hypothyroidism. Although numerous websites continue to advocate the use of thyroid hormone extracts as a superior therapy for hypothyroidism, none of the most recent guidelines of major endocrine societies recommend thyroid extract use for hypothyroidism.Abbreviations: AACE = American Association of Clinical Endocrinologists ATA = American Thyroid Association BMR = basal metabolic rate FDA = Food and Drug Administration FT4 = free thyroxine 131-I = radioactive iodine 131 LT3 = liothyronine LT4= levothyroxine NDA = new drug application PBI = proteinbound iodine T3 = triiodothyronine T4 = thyroxine TSH = thyroid-stimulating hormone TT3 = total triiodothyronine USP = U.S. Pharmacopeia |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|